Daclatasvir + asunaprevir combination regimen - Bristol-Myers Squibb

Drug Profile

Daclatasvir + asunaprevir combination regimen - Bristol-Myers Squibb

Alternative Names: Asunaprevir + daclatasvir; BMS-790052 + BMS-650032; Daklinza + Sunvepra; DCV Dual Regimen (daclatasvir and asunaprevir combination therapy); DCV+ASV Dual Regimen

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Amides; Biphenyl compounds; Carbamates; Cyclopropanes; Imidazoles; Isoquinolines; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 01 Nov 2016 Kaohsiung Medical University Chung-Ho Memorial Hospital initiates the phase III DARING trial for Hepatitis C (Combination therapy) in Taiwan (PO) (NCT03004625)
  • 01 Oct 2016 Bristol-Myers Squibb and Tokai University School of Medicine initiate a clinical trial for Hepatitis C in Japan (PO) (UMIN000024261)
  • 22 Feb 2016 Final efficacy and adverse events data from a phase III trial in Hepatitis C released by Bristol-Myers Squibb (9191573; NCT1995266)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top